Article

Abundant evidence underlines pressure dependency of glaucoma damage

While results of epidemiologic studies indicate that only one-third of glaucoma damage is attributable to excess IOP over the normal distribution, much more of glaucoma damage appears to be pressure-dependent and therefore preventable, especially in patients whose IOP is higher than average, said Paul F. Palmberg, MD, PhD.

Chicago-While results of epidemiologic studies indicate that only one-third of glaucoma damage is attributable to excess IOP over the normal distribution, much more of glaucoma damage appears to be pressure-dependent and therefore preventable, especially in patients whose IOP is higher than average, said Paul F. Palmberg, MD, PhD.

Dr. Palmberg delivered the Robert N. Shaffer Lecture during a combined meeting with Prevent Blindness America held during the annual meeting of the American Academy of Ophthalmology. He is known for introducing the term “target pressure” in 1989, and he spoke on “How much of glaucoma damage is pressure-dependent?”

Dr. Palmberg said that although epidemiologic studies have found a weak relationship between IOP and glaucomatous damage, closer examination of the data from those trials reveals that low normal pressures may be protective. He went on to review findings from a number of clinical studies published over the last two decades supporting that concept. The best evidence derives from the large, prospective, multicenter, National Eye Institute-sponsored randomized clinical trials. Collectively, those studies demonstrate that aggressive intervention to lower IOP to a target level is helpful in patients with advanced glaucoma, normal-tension glaucoma, and those with early disease.

Dr. Palmberg concluded by crediting Paul Chandler, MD, as first suggesting the importance of seeking lower target pressures in some glaucoma patients in a 1960 landmark paper in the American Journal of Ophthalmology.

“It turns out we are back to the future and that Paul Chandler said it best when he suggested that patients with advanced glaucoma with damage at both poles require an IOP below the average normal to be stable, eyes with limited cupping confined to one pole of the disc appear to withstand tension better, and perhaps can do well with an IOP in the mid-to-upper normal range, while those with a normal appearing disc may be able to withstand ocular hypertension for years without sustaining glaucomatous damage. The appearance of the disc may be the best guide as to the effect of IOP on the eye and how to manage glaucoma,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.